These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 32569363)

  • 21. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
    Della-Torre E; Campochiaro C; Cavalli G; De Luca G; Napolitano A; La Marca S; Boffini N; Da Prat V; Di Terlizzi G; Lanzillotta M; Rovere Querini P; Ruggeri A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; De Cobelli F; Dagna L; ;
    Ann Rheum Dis; 2020 Oct; 79(10):1277-1285. PubMed ID: 32620597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of tocilizumab effect on mortality in COVID19 patients.
    Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
    Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.
    Pereira MR; Mohan S; Cohen DJ; Husain SA; Dube GK; Ratner LE; Arcasoy S; Aversa MM; Benvenuto LJ; Dadhania DM; Kapur S; Dove LM; Brown RS; Rosenblatt RE; Samstein B; Uriel N; Farr MA; Satlin M; Small CB; Walsh TJ; Kodiyanplakkal RP; Miko BA; Aaron JG; Tsapepas DS; Emond JC; Verna EC
    Am J Transplant; 2020 Jul; 20(7):1800-1808. PubMed ID: 32330343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective treatment of severe COVID-19 patients with tocilizumab.
    Xu X; Han M; Li T; Sun W; Wang D; Fu B; Zhou Y; Zheng X; Yang Y; Li X; Zhang X; Pan A; Wei H
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10970-10975. PubMed ID: 32350134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge.
    Sinha P; Mostaghim A; Bielick CG; McLaughlin A; Hamer DH; Wetzler LM; Bhadelia N; Fagan MA; Linas BP; Assoumou SA; Ieong MH; Lin NH; Cooper ER; Brade KD; White LF; Barlam TF; Sagar M;
    Int J Infect Dis; 2020 Oct; 99():28-33. PubMed ID: 32721528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Selles P; Zahra H; Kadiane-Oussou NJ; Toko L; Royer PY; Balblanc JC; Gendrin V; Conrozier T;
    Int J Infect Dis; 2020 Oct; 99():491-495. PubMed ID: 32798660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
    Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
    Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
    Wang L; Peng X; Wang ZH; Cai J; Zhou FC
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.
    Patel A; Shah K; Dharsandiya M; Patel K; Patel T; Patel M; Reljic T; Kumar A
    Indian J Med Microbiol; 2020; 38(1):117-123. PubMed ID: 32719218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
    Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
    Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
    Perrone F; Piccirillo MC; Ascierto PA; Salvarani C; Parrella R; Marata AM; Popoli P; Ferraris L; Marrocco-Trischitta MM; Ripamonti D; Binda F; Bonfanti P; Squillace N; Castelli F; Muiesan ML; Lichtner M; Calzetti C; Salerno ND; Atripaldi L; Cascella M; Costantini M; Dolci G; Facciolongo NC; Fraganza F; Massari M; Montesarchio V; Mussini C; Negri EA; Botti G; Cardone C; Gargiulo P; Gravina A; Schettino C; Arenare L; Chiodini P; Gallo C;
    J Transl Med; 2020 Oct; 18(1):405. PubMed ID: 33087150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.
    Mohebbi N; Abedini A; Lashgari R; Razavi F; Varahram M; Kiani A
    Adv Respir Med; 2020; 88(5):468-469. PubMed ID: 33169824
    [No Abstract]   [Full Text] [Related]  

  • 40. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
    Jiménez-Brítez G; Ruiz P; Soler X
    Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.